Nykode Therapeutics : Nycode Therapeutics – Clinical development plan for VB10.16 – presentation
December 20, 2022 at 05:18 am EST
Share
VB10.16
Outline of further clinical development in HPV16-positive malignancies
December 20, 2022
Forward-looking statement
This announcement and any materials distributed in connection with this presentation may contain certain forward- looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company's current expectations and assumptions as to future events and circumstances that may not prove accurate.
A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
Nykode Therapeutics | VB10.16 development plan | Non -confidential
2
Today's presenters from Nykode management
MICHAEL ENGSIG
Chief Executive
Officer
Wide-ranging experience from leading early-stage drug discovery through late-stage and
commercial development
Takeda
and Nycomed
PPD
KLIFO
AGNETE FREDRIKSEN
Chief Business Officer & Co-founder
More than 20 years experience with APC- targeted vaccines from drug discovery to clinical development in various leadership positions at
Vaccibody/Nykode
KLAUS EDVARDSEN
Chief Development Officer
Extensive experience from leading drug development programs within oncology, hematology and infectious
diseases in both biotech and pharma companies:
CureVac (as CDO)
Merck KGaA
AstraZeneca
Nykode Therapeutics | VB10.16 development plan | Non -confidential
3
VB C-02: VB10.16 + Atezolizumab (Tecentriq®) in advanced Cervical Cancer - Study on track
Multi-Centre,Single Arm, Open-label Phase 2a Trial of the Combination of VB10.16 and atezolizumab in Patients with Advanced or Recurrent, Non-resectable HPV16 Positive Cervical Cancer (NCT04405349)
Objectives: safety/tolerability, immunogenicity and efficacy
Primary endpoints: incidence/severity of AEs, ORR (based on RECIST 1.1 by blinded independent central review)
Fully enrolled with 52 patients
Conducted in Europe in 6 countries (Germany, Belgium, Bulgaria, Czech Republic, Poland and Norway)
Enrolled patients received treatment with 3 mg VB10.16 in combination with 1200 mg atezolizumab for up to 48 weeks
Advanced
12 MONTHS
or recurrent,
Vaccination
Vaccination
non-respectable
HPV16-positive
induction
maintenance
cervical cancer
12 MONTHS
Follow-up
Nykode Therapeutics | VB10.16 development plan | Non -confidential
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Nykode Therapeutics AS published this content on 20 December 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 December 2022 10:16:18 UTC.
Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeuticsâ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.